This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Astellas Pharma Gmbh, Riken Corporation. Active years: 2023.
Company Filing History:
1 out of 424 
1 out of 889 
Years Active: 2023
Title: Ayaka Akiba: Innovator in Cancer Treatment
Introduction
Ayaka Akiba is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer treatment through her innovative research and development. Her work focuses on creating effective therapeutic solutions for patients suffering from cancer.
Latest Patents
Ayaka Akiba holds a patent for a groundbreaking invention titled "NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer." This invention aims to provide clinically applicable aAVC-NY-ESO-1 cells that stably express NY-ESO-1. These cells are designed to treat patients with NY-ESO-1-expressing cancers. The invention includes a human-derived cell that comprises a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, with the latter operably linked to an inducible promoter.
Career Highlights
Throughout her career, Ayaka Akiba has worked with notable companies in the pharmaceutical and biotechnology sectors. She has been associated with Astellas Pharma GmbH and Riken Corporation, where she has contributed to various research initiatives aimed at advancing cancer therapies.
Collaborations
Ayaka has collaborated with esteemed colleagues, including Shinichiro Fujii and Keisuke Ohsumi. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in cancer treatment.
Conclusion
Ayaka Akiba is a trailblazer in the field of cancer research, with her patent and collaborations reflecting her commitment to improving patient outcomes. Her work continues to inspire advancements in medical science and innovation.